Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise awareness of and funds for…
News
Technologies to prevent, detect, and treat viral hepatitis have advanced considerably in recent decades, but the number of people dying from these infections continues…
CHOLANGITIS
NewsElafibranor for PBC may become Genfit’s first approved molecule
Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…
CHOLESTASIS
NewsNonprofit funds research to test for pregnancy complication ICP
A nonprofit group has donated $60,000 to support researchers at Yale University School of Medicine working to expand access to a new test that can…
FATTY LIVER DISEASE
NewsFatty liver disease treatment DD01 gets FDA fast track designation
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DD01 as a potential treatment for a severe manifestation of fatty…
ALAGILLE SYNDROME
NewsPruritus treatment Livmarli should be reimbursable: Canadian panel
A Canadian Agency for Drugs and Technologies in Health (CADTH) committee has recommended that Livmarli (maralixibat) be covered by the country’s publicly funded health…
The U.S. Food and Drug Administration (FDA) has again expanded its approval of Gilead Sciences’ medication Vemlidy (tenofovir alafenamide) for chronic hepatitis B…
CHOLANGITIS
NewsLB-P8 probiotic on FDA fast track for primary sclerosing cholangitis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to LB-P8, LISCure Biosciences’ experimental live bacterium product that is headed toward…
CHOLESTASIS
NewsBrain changes seen in children with neonatal cholestasis: Study
Brain scans have shown children with neonatal cholestasis tend to have brain abnormalities, a review study found. Bleeding was the most common, especially in…
FATTY LIVER DISEASE
NewsChiglitazar lowers MASH patients’ liver fat accumulation: Phase 2 trial
Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 diabetes in China, led to significant reductions in liver fat accumulation among people with nonalcoholic…
Recent Posts
- Living with MASH reminds me to avoid making assumptions
- Particles in grilled meats may trigger liver disease, mouse study finds
- Supporting my oldest son, who’s growing up with a chronically ill sibling
- Human trial testing gene silencing injection therapy for MASH kicks off
- Blood bile acids predict liver outcomes in Alagille syndrome children: Study